Medical technology giant BD on Tuesday announced millions in additional investments that are expected to create 300 new jobs across its four Nebraska facilities.
The company plans to spend $200 million in Columbus, where one plant produce needles and syringes and another makes glass syringes for the pharmaceutical industry.
The new funding adds to $100 million previously spent at its Holdrege facility, which makes insulin and diabetes-care syringes and alcohol swabs, as well as $40 million invested in Broken Bow, where BD produces blood collection tubes and urine collection products.
Those four sites currently employ about 2,700 workers overall, according to the Bio Nebraska Life Sciences Association. The company employs some 65,000 people worldwide.
State officials said recruiting efforts for the new positions would particularly focus on veterans and service members returning to civilian life, including a multi-agency initiative to create a pipeline of skilled workers with two-year advanced degrees.
BD chief supply chain officer Jim Borzi credited the “extraordinary” public-private partnership with state government for the New Jersey-based company’s rapid expansion in Nebraska.
Image Credit: Marian Weyo / Shutterstock.com
